Article

Evaluation of Toxicity and Effect on Growth and Sexual Development in Children with MAPK Pathway Driven Tumors Treated with BRAF and MEK Inhibitors -- A Single Center Experience

2020-10-09

Abstract excerpt

<h4>Background: </h4> The MAPK pathway, is a signal transduction pathway involved in the oncogenesis of a variety of pediatric tumors. The clinical use of BRAF inhibitors and MEK inhibitors is increasingly used in oncology practice. The toxicity profile of these drugs in the pediatric population, particularly in relation to development, growth and sexual maturation remains insufficiently studied. Procedure This st...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: eccd752d-2221-549d-9655-0cf0736ae338
DOI: 10.22541/au.160225762.21068105/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Evaluation of Toxicity and Effect on Growth and Sexual Development in Children with MAPK Pathway Driven Tumors Treated with BRAF and MEK Inhibitors -- A Single Center ExperienceDOI 10.22541/au.160225762.21068105/v1Read

Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationSemantic proximity Read

BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities.Semantic proximity Read

Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and SelumetinibSemantic proximity Read

Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients.Semantic proximity Read

Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success.Semantic proximity Read

MEK genomics in development and disease.Semantic proximity Read

Dermatological adverse events from BRAF inhibitors: a growing problem.Semantic proximity Read

Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential usesSemantic proximity Read

Cutaneous adverse events in children treated with vemurafenib for refractory BRAFV600E mutated Langerhans cell histiocytosis.Semantic proximity Read

Vemurafenib provides a rapid and robust clinical response in paediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease based on ddPCR using cell-free circulating DNASemantic proximity Read

Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish.Semantic proximity Read

The clinical development of MEK inhibitorsSemantic proximity Read